| Title: |
Disease activity in pregnant and postpartum women with multiple sclerosis receiving ocrelizumab or other disease-modifying therapies |
| Authors: |
Yeh, Wei Z.; Van Der Walt, Anneke; Skibina, Olga G.; Kalincik, Tomas; Alroughani, Raed; Kermode, Allan G.; Fabis-Pedrini, Marzena J.; Carroll, William M.; Lechner-Scott, Jeannette; Boz, Cavit; Ozakbas, Serkan; Buzzard, Katherine; Habek, Mario; John, Nevin A.; Prat, Alexandre; Girard, Marc; Duquette, Pierre; Baghbanian, Seyed Mohammad; Hodgkinson, Suzanne; Van Pesch, Vincent; Laureys, Guy; Willekens, Barbara; Prevost, Julie; Foschi, Matteo; De Gans, Koen; Horakova, Dana; Havrdova, Eva Kubala; Karabudak, Rana; Patti, Francesco; Mccombe, Pamela A.; Maimone, Davide; Altintas, Ayse; Ampapa, Radek; Spitaleri, Daniele; Gerlach, Oliver H.H.; Sa, Maria Jose; Hughes, Stella; Gouider, Riadh; Mrabet, Saloua; Macdonell, Richard A.; Turkoglu, Recai; Cartechini, Elisabetta; Al-Asmi, Abdullah; Soysal, Aysun; Oh, Jiwon; Muros-Le Rouzic, Erwan; Guye, Sabrina; Pasquarelli, Noemi; Butzkueven, Helmut; Jokubaitis, Vilija G.; Van Hijfte, Liesbeth; for the MSBase Study Group, missing |
| Source: |
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION ; ISSN: 2332-7812 |
| Publication Year: |
2024 |
| Collection: |
Ghent University Academic Bibliography |
| Subject Terms: |
Medicine and Health Sciences; NATALIZUMAB; PLACEBO; RELAPSE |
| Description: |
Background and Objectives Women with multiple sclerosis (MS) are at risk of disease reactivation in the early postpartum period. Ocrelizumab (OCR) is an anti-CD20 therapy highly effective at reducing MS disease activity. Data remain limited regarding use of disease-modifying therapies (DMTs), including OCR, and disease activity during peripregnancy periods. Methods We performed a retrospective cohort study using data from the MSBase Registry including pregnancies conceived after December 31, 2010, from women aged 18 years and older, with relapsing-remitting MS or clinically isolated syndrome. Women were classified by preconception exposure to DMTs, including OCR, rituximab (RTX), natalizumab (NAT), stratified into active (NAT-A; continued >= 28 weeks of gestation, restarted |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| Relation: |
https://biblio.ugent.be/publication/01JCWVPVKQGPYYQ64TH3HJBH2V; https://doi.org/10.1212/nxi.0000000000200328; https://biblio.ugent.be/publication/01JCWVPVKQGPYYQ64TH3HJBH2V/file/01JCWVQQHAVBN9HF4M20XHJNWR |
| DOI: |
10.1212/nxi.0000000000200328 |
| Availability: |
https://biblio.ugent.be/publication/01JCWVPVKQGPYYQ64TH3HJBH2V; https://hdl.handle.net/1854/LU-01JCWVPVKQGPYYQ64TH3HJBH2V; https://doi.org/10.1212/nxi.0000000000200328; https://biblio.ugent.be/publication/01JCWVPVKQGPYYQ64TH3HJBH2V/file/01JCWVQQHAVBN9HF4M20XHJNWR |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.1887F44B |
| Database: |
BASE |